Richard G. Moore Adjunct Professor of Obstetrics and Gynecology

Dr. Moore is a Gynecologic Oncologist and research scientist in The Program in Women’s Oncology at Women and Infants Hospital / Brown University and is a Professor of Obstetrics and Gynecology at the Warren Alpert Medical School of Brown University.  Dr. Moore is the director of the Molecular Therapeutics Laboratory, The Center for Biomarkers and Emerging Technology (CBET) as well as the Associate Director for The Program in Women’s Oncology at Women and Infants Hospital.  Dr. Moore’s research interests include investigation of oncogenic pathways and clinical trials in gynecologic cancer with a special emphasis on biomarker research and novel therapies for ovarian cancer. Dr. Moore is recognized as a national and international expert on biomarkers for the detection of ovarian cancer and led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that was recently cleared by the US FDA, which detects ovarian cancer in women with an ovarian cyst or pelvic mass. ROMA is now available for clinical use worldwide.

Brown Affiliations

Research Areas

scholarly work

1) Moore RG, Steinhoff MM, Granai CO, DeMars LR. Case Report: Vulvar epithelioid sarcoma in pregnancy. Gynecologic Oncology, 2002; 85, 218-222 PM: 11925150

2) Moore RG, DePasquale SE, Steinhoff MM, Gajewski W, Steller MA, Falkenberry SS. Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in vulvar malignancies. Gynecologic Oncology, 2003; 89, 475-479 PM: 12798714

3) Moore RG, Granai CO, Gajewski W, Gordinier M, Steinhoff M. Pathologic evaluation of inguinal sentinel nodes in vulvar cancer patients: A comparison of immunohistochemical staining versus ultra-staging with hematoxylin and eosin staining. Gynecologic Oncology, 2003; 91, 378-382. PM: 14599869

4) Moore RG, Chung M, Gajewski W, Granai CO, Steinhoff M. Incidence of metastasis to the ovaries from non-genital tract primary tumors. Gynecologic Oncology, 2004; 93, 87-91 PM: 15047218

5) Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, DiSilvestro P, Gordinier ME, Moore RG, Granai C.O. and Legare RG. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecologic Oncology, 2006; 100, 149-151 PM: 16197986

6) Robison K, Granai CO, Brard L, Gajewski W, Steinhoff M, Moore RG. Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. Gynecologic Oncology, 2006; 101, 24-27 PM: 16246399

7) Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, DiSilvestro P, Gordinier M, Moore RG, Tejada-Berges T, Pires L, Legare R, Granai C.O.. Two more for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer. Gynecologic Oncology, 2006; 100, 417-421 PM: 16336992

8) Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecologic Oncology,2006; 103 (1), 176-180 PM: 16564074

9) Brown AK, Madom LM, Moore RG, Granai CO, DiSilvestro PA The Prognostic Significance of Lower Uterine Segment Involvement in Surgically Staged Endometrial Cancer Patients with Negative Nodes. Gynecology Oncology, 2007: 105, 55-58 PM: 17157904

10) Gordinier ME, Dizon DS, Weitzen S, DiSilvestro PA, Moore RG, Granai, CO Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer. J Palliat Med, 2007; 10(1), 61-6

11) Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro PA. Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma. Gynecologic Oncology, 2007, 107(1), 75-78 PM: 17629550

12) Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Sommers E, Allard J, Moore RG, Lu K, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment Gynecologic Oncology, 2007, 106(3), 490-497 PM: 17532030

13) Moore RG, Brown AK, Miller CM, Skates S, Allard JW, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai C.O., Bast R. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 2008, 108(2), 402-408 PM: 18061248

14) Moore RG, Robison K, Brown AK, Brard L, DiSilvestro PA, Steinhoff MM, Noto R, Granai CO. Isolated Sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A Prospective Trial. Gynecologic Oncology, 2008, 109, 65-70 PM: 18255128

15) Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW, Granai C.O., Bast R, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. Gynecologic Oncology, 2008, 110, 196-201 PM: 18495222

16) Moore RG, Robison K, Steinhoff M. The utility of immunohistochemical staining for detection of metastatic disease in sentinel lymph nodes. Invited editorial Gynecologic Oncology, 2008, 111 (1), 159

17) Moore RG, McMeeken S, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast Jr R, Skates S. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 2009, 112, 40-46 PM: 18851871

18) Rardin CR, Moore RG, Ward RM, Myers DL. Recurrent thigh abscess with necrotizing fasciitis from a retained transobturator sling segment. Journal of Minimally Invasive Gynecology, 2009, 16(1), 84-87 PM: 19110187

19) Clement A, Robison K, Steinhoff M, Scalia-Wilbur J, Moore RG. A Case of Peutz Jeghers Syndrome with Breast Cancer, Bilateral Sex Cord Tumor with Annular Tubules and Adenoma Malignum caused by STK11 Gene Mutation. International Journal of Gynecologic Cancer, 2009, 19(9),1591-1594 PM: 19955943

20) Allard JW and Moore RG. The novel biomarker HE4 improves the sensitivity of CA125 alone for monitoring and differential diagnosis of ovarian cancer. Clinical Laboratories International, 2009, 3, 20-21

21) Moore RG, Jabre-Raughley M, Brown AK, Robison KM, M. Miller MC, Allard WJ, Kurman RJ, Bast Jr RC, Skates SJ. Comparison of a Novel Multiple Marker Assay Versus the Risk of Malignancy Index for the Prediction of Epithelial Ovarian Cancer in Patients with a Pelvic Mass. The American Journal of Obstetrics and Gynecology,2010, 203, 3, 228.e1 – 228.e6 DOI: 10.1016/j.ajog.2010.03.043

22) Krotz SP, Robins JC, Ferruccio TM, Moore RG, Steinhoff MM, Morgan JR, Carson S. In vitro maturation of oocytes via the pre-fabricated self-assembled artificial human ovary. Journal of Assisted Reproductive Genetics, 2010, 27(12):743-50 DOI 10.1007/s10815-010-9468-6

23) Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS. Organometallic Iron(III)-salophene exerts cytotoxic properties in Neuroblastoma cells via MAPK activation and ROS generation. PLOS ONE, 2011, 6 (4), 1-10 e19049 PM: 21559503

24) Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines Gynecologic Oncology, 2011, 122(1), 183-189 PM: 21529906

25) Moore RG, Miller MC, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of Tumor Marker HE4 to Predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. International Journal of Gynecologic Cancer, 2011, 21 (7), 1185-1190 DOI: 10.1097/IGC.0b013e3182229ad8

26) Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. Gynecologic Oncology, 2011, PM: 21803404

27) Moore RG, Miller MC, Disilvestro P, Landrum L, Gajewski W, Jeff J. Ball, Skates SJ. Evaluation of the Risk of Ovarian Malignancy Algorithm in women with a pelvic mass presenting to general gynecologists. Obstetrics and Gynecology, 2011, 118 (2) PART 1, pp 280-288 DOI: 10.1097/AOG.0b013e318224fce2

28) Kim KK, Singh AP, Singh RK, DiMartino A, Brard L, Vorsa N, Lange TS, Moore RG. Anti-angiogenic activity of cranberry proanthocynidines and cytotoxic properties in ovarian cancer cells. International Journal of Oncology, 2011; 40(1):227-35 DOI: 10.3892/ijo.2011.1198

29) Horan TC, Zompa MA, Seto CT, Kim KK, Moore RG, Lange TS (2011) Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines. Investigational New Drugs, July 26, 2011. PMID: 21809024 DOI: 10.1007/s10637-011-9728-z

30) Kim KK, Singh RK, Strongin RM, Brard L, Moore RG, Lange TS. Organometallic Iron(III)-salophene exerts cytotoxic properties in Neuroblastoma cells via MAPK activation and ROS generation. PLOS ONE. April 29, 2011, PLoS ONE 6:e19049 DOI:10.1371/journal.pone.0019049

31) Lange TS, Horan T, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK. Cytotoxic Properties of Adamantyl Isothiocyanate and Potential In vivo Metabolite Adamantyl-N-Acetylcystein in Gynecological Cancer Cells Chemical Biology & Drug Design, January 2012, 79 (1), pp 92–103. DOI: 10.1111/j.1747-0285.2011.01251.x

32) Singh AP, Lange TS, Kim KK, Brard L, Horan TC, Moore RG, Vorsa N, Singh RK. Purified Cranberry proanthocynidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. International Journal of Oncology, 2012, 40 (1), 99-108 DOI:10.3892/ijo.2011.1225

33) Quddus MR, Sung CJ, Zhang C, Moore RG, Ou JJ, Steinhoff MM, Lawrence WD. The Presence of Epithelial Implants and Implants with Epithelial Proliferation and Their Locations May Predict a Higher Risk of Recurrence in Serous Borderline Ovarian Tumors: A Clinicopathologic Study of 188 cases. Human Pathology: 2012, 43, 747–752 DOI:10.1016/j.humpath.2011.06.023

34) Zhang C, Quddus MR, Sung CJ, Moore RG, Lawrence WD. Vulvar encapsulated solid papillary carcinoma with neuroendocrine differentiation: case report and literature review International Journal of Surgical Pathology, 2012, 20 (1), pp 97-100 DOI: 10.1177/1066896911401387

35) Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum Levels of the Ovarian Cancer Biomarker HE4 are decreased in Pregnancy and Increase with Age. American Journal of Obstetrics and Gynecology, 2012; 206:349.e1-7. DOI: 10.1016/j.ajog.2011.12.028

36) Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology.2012; 206:351.e1-8 DOI: 10.1016/j.ajog.2011.12.029

37) Kim KK, Lange TS, Singh RK, Brard L, Moore RG. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C BMC Cancer 2012, 12:147 DOI:10.1186/1471-2407-12-147)

38) Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, Depaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK. Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model Plos One, 2012; 7(4):e34443. PMID: 22509304

39) Kristjansdottir K, Kim KK, Choi JS, Horan TC, Bard L, Moore RG, Singh R. 7-Methyl Indole Ethyl Isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. Gynecologic Oncology, 2012, 126(2):252-8 PMID: 22561404

40) Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Zaino R. Etiologic Heterogeneity in Endometrial Cancer: Evidence from a Gynecologic Oncology Group Trial. Gynecologic Oncology 2013 May;129 (2):277-84. PMID: 23485770 DOI: 10.1016/j.ygyno.2013.02.023.

41) Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore RG, Granai CO, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun C, Horick N, Fritsche H, Bast RC. A two stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 August 26. PM:23983047 DOI: 10.1002/cncr.28183

42) Rutherford T, Orr J, Grendys E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecologic Oncology; 8/13/201; PM:23954900 DOI: 10.1016/j.ygyno.2013.08.009

43) Wang J, Sibrian-Vazquez M, Escobedo JO, Lowry M, Wang L, Chu YH, Moore RG, Strongin RM. Simple enrichment and analysis of plasma lysophosphatidic acid Analyst, 2013, 138, pp 6852–6859 DOI: 10.1039/c3an01168b

44) Kawar N, Maclaughlan S, Horan TC, Uzun A, Kim KK, Lange T, Kim KK, Hopson R, Singh A, Glass K, Shaw S, Padbury JF, vorsa N, Arnold A, Moore RG, Brard L, Singh RK. PT19c, another non-hypercalcemic vitamin D2 derivative, demonstrates antitumor efficacy in epithelial ovarian and endometrial cancer. Genes and Cancer, 2013, October 30, pp 1-11 DOI: 10.1177/1947601913507575

45) Moore RG, Hill EK, Horan T, Yano N, Kim KK, Maclaughlan S, Lambert-Messerlian G, Tseng YTD, Padbury JF, Miller MC, Lange TS, Singh RK. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Scientific Reports, Nature publishing, 2013, 4, 3574 pp1-7. DOI: 10.1038/srep03574

46) Krivak TC, Lele S, Richard S, Alvarez Secord A4, Leath III CA, Brower SL, Tian C, Moore RG. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. In Press. American Journal of Obstetrics and Gynecology

47) Robison K, Roque DR, McCourt C, Stuckey A, DiSilvestro P, Sung J, Steinhoff M, Raker C, Granai C.O., Moore RG. Isolated Sentinel Lymph Node Biopsy with Conservative Management in Women Diagnosed with Vulvar Cancer. In Press: Gynecologic Oncology

funded research

Isolation of Human Papillomavirus type 18 genomic integration sites in squamous cell carcinoma of the cervix. PI: Richard G. Moore The Kettering Family Foundation Grant: $15,000 2000-2001

Early detection of epithelial ovarian cancer. The University of Texas M..D. Anderson Cancer Center SPORE in ovarian cancer. Site PI: Richard G. Moore University of Texas M.D. Anderson Cancer Center SPORE. NCI/NIH P50 CA083639 Ovarian SPORE Site funding: $100,000. 2003-Current

A pilot study of the utility of CA-125, soluble mesothelin related peptides (SMRP) and HE4 levels in the pre-operative diagnosis of epithelial ovarian carcinoma. PI: Richard G. Moore Fujirebio Diagnostics Inc. Grant: $50,000. 2004-2006

Evaluation of multiple biomarker assays to estimate risk of ovarian cancer in patients presenting with a pelvic mass. (FDI-03) PI: Richard G. Moore Fujirebio Diagnostics Inc. Budget: $1,200,000. 2005-2006

Evaluation of ROMA in patients presenting with a pelvic mass to gynecologists. (FDI-15) PI: Richard G. Moore Fujirebio Diagnostics Inc. Budget: $2,000,000 2009-2010

Evaluation of the serum biomarker HE4 for monitoring patients with Epithelial Ovarian Cancer. PI: Richard G. Moore Abbott Diagnostics Inc. Grant $66,600 2010-Current

Research Development Grant Swim Across America: PI: Richard G, Moore $250,000 2010-current

NCI RO1: Development of an assay for the early detection of ovarian cancer. PI: Richard G. Moore Grant #: 1 RO1 CA136491-01 5 years (2009-2014): $2,376,792

NCI RO1: Urine and serum biomarkers for screening and diagnosis of ovarian cancer. Sub-contract PI: Richard G. Moore Grant #: 2 R01 CA108990-06 5 years (2010-2015): $626,577

Fujirebio Unrestricted Grant to CBET PI: Richard G. Moore Annual Stipend: $75,000 2010-current Evaluation of HE4 throughout the menstrual cycle.

Abbott Diagnostics Inc. Grant $8,000 2011-current

Evaluation of the serum biomarker HE4 for monitoring patients with endometrial cancer Fujirebio Diagnostics Inc. Pi: Richard G. Moore Grant $80,000 2011-current